VBL shares obliterated by ovarian cancer failure
Israeli-American company VBL Therapeutics (Nasdaq:VBLT) was trading 79% lower in Wednesday’s pre-market activity.
VBL, which is developing targeted medicines for cancer and immune-inflammatory diseases, announced disappointing top-line data from the Phase III OVAL trial of ofra-vec (ofranergene obadenovec; VB-111) in platinum-resistant ovarian cancer.
"We plan to discontinue the OVAL trial and will review the data from our ongoing Phase II trials in metastatic colorectal cancer and recurrent glioblastoma multiforme to determine next steps with the ofra-vec program"The trial did not meet the primary endpoints of achieving a statistically-significant improvement in progression-free survival (PFS) or overall survival (OS).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze